JP5421108B2 - ２−フェノキシピリミジノン類縁体 - Google Patents

２−フェノキシピリミジノン類縁体 Download PDF

Info

Publication number
JP5421108B2
JP5421108B2 JP2009525630A JP2009525630A JP5421108B2 JP 5421108 B2 JP5421108 B2 JP 5421108B2 JP 2009525630 A JP2009525630 A JP 2009525630A JP 2009525630 A JP2009525630 A JP 2009525630A JP 5421108 B2 JP5421108 B2 JP 5421108B2
Authority
JP
Japan
Prior art keywords
alkyl
fluorophenyl
purin
dihydro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009525630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502576A (ja
JP2010502576A5 (enExample
Inventor
バクサヴァッチャラム ラージャゴーパール
マイケル キャピトスティ スコット
シュウ ジャンジュン
エル シェナード バートランド
ゴーシュ マヌカ
エイ ブルム チャールズ
Original Assignee
ニューロジェン・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロジェン・コーポレーション filed Critical ニューロジェン・コーポレーション
Publication of JP2010502576A publication Critical patent/JP2010502576A/ja
Publication of JP2010502576A5 publication Critical patent/JP2010502576A5/ja
Application granted granted Critical
Publication of JP5421108B2 publication Critical patent/JP5421108B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
JP2009525630A 2006-08-23 2007-08-22 ２−フェノキシピリミジノン類縁体 Expired - Fee Related JP5421108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82325806P 2006-08-23 2006-08-23
US60/823,258 2006-08-23
PCT/US2007/018654 WO2008024438A2 (en) 2006-08-23 2007-08-22 2-phenoxy pyrimidinone analogues

Publications (3)

Publication Number Publication Date
JP2010502576A JP2010502576A (ja) 2010-01-28
JP2010502576A5 JP2010502576A5 (enExample) 2010-10-07
JP5421108B2 true JP5421108B2 (ja) 2014-02-19

Family

ID=39107411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525630A Expired - Fee Related JP5421108B2 (ja) 2006-08-23 2007-08-22 ２−フェノキシピリミジノン類縁体

Country Status (22)

Country Link
US (2) US8003656B2 (enExample)
EP (1) EP2061794B1 (enExample)
JP (1) JP5421108B2 (enExample)
KR (1) KR20090043583A (enExample)
CN (2) CN104292229A (enExample)
AU (1) AU2007288203B2 (enExample)
BR (1) BRPI0716582A2 (enExample)
CA (1) CA2660957C (enExample)
CO (1) CO6150167A2 (enExample)
CR (1) CR10675A (enExample)
EA (1) EA200900330A1 (enExample)
ES (1) ES2399928T3 (enExample)
GT (1) GT200900040A (enExample)
IL (1) IL197043A0 (enExample)
MA (1) MA30720B1 (enExample)
MX (1) MX2009002066A (enExample)
NI (1) NI200900023A (enExample)
NO (1) NO20091182L (enExample)
SV (1) SV2009003173A (enExample)
TW (1) TW200825089A (enExample)
WO (1) WO2008024438A2 (enExample)
ZA (1) ZA200901163B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
AU2007288203B2 (en) 2006-08-23 2013-01-17 Neurogen Corporation 2-phenoxy pyrimidinone analogues
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SI3417851T1 (sl) 2013-09-09 2020-11-30 Peloton Therapeutics, Inc. Aril etri in njihova uporaba
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20220071953A1 (en) * 2019-01-08 2022-03-10 Texas Tech University System Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
DK0807633T3 (da) 1996-05-15 2002-11-25 Pfizer Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
EP0982992B1 (en) 1997-05-08 2002-09-25 Aventis CropScience UK Limited Use of thienopyrimidines as fungicides
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
AU2002214546A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
CA2433778A1 (en) 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
IL157815A0 (en) 2001-03-26 2004-03-28 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
US20070125454A1 (en) * 2001-09-28 2007-06-07 Konrad Eipper High-strength duplex/triplex steel for lightweight construction and use thereof
EP1461311A2 (en) 2001-12-26 2004-09-29 Bayer HealthCare AG Urea derivatives as vr1-antagonists
ATE533743T1 (de) 2002-05-17 2011-12-15 Janssen Pharmaceutica Nv Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
AU2003273856A1 (en) 2002-09-24 2004-04-19 Bayer Healthcare Ag Vr1 antagonists for the treatment of urological disorders
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
GB0326633D0 (en) 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
AU2004290626A1 (en) * 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2006122200A1 (en) 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
CN1318429C (zh) * 2005-07-25 2007-05-30 华中师范大学 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3－d]嘧啶－4(3H)－酮及制备
AU2006311883A1 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
AU2007288203B2 (en) 2006-08-23 2013-01-17 Neurogen Corporation 2-phenoxy pyrimidinone analogues
EP2061470A4 (en) 2006-08-23 2010-10-06 Neurogen Corp HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES
CA2668579A1 (en) 2006-11-06 2008-06-05 Neurogen Corporation Cis-cyclohexyl substituted pyrimidinone derivatives
WO2008156607A1 (en) 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
WO2009100403A1 (en) 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
WO2009121036A2 (en) 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives

Also Published As

Publication number Publication date
MX2009002066A (es) 2009-03-06
NI200900023A (es) 2010-03-05
KR20090043583A (ko) 2009-05-06
AU2007288203B2 (en) 2013-01-17
GT200900040A (es) 2010-03-16
JP2010502576A (ja) 2010-01-28
CR10675A (es) 2009-04-17
CN104292229A (zh) 2015-01-21
CN101506210A (zh) 2009-08-12
US8003656B2 (en) 2011-08-23
BRPI0716582A2 (pt) 2013-10-08
IL197043A0 (en) 2009-11-18
EP2061794A2 (en) 2009-05-27
EA200900330A1 (ru) 2009-08-28
ZA200901163B (en) 2010-08-25
CA2660957C (en) 2016-10-11
SV2009003173A (es) 2010-08-10
WO2008024438A2 (en) 2008-02-28
MA30720B1 (fr) 2009-09-01
US20090069347A1 (en) 2009-03-12
ES2399928T3 (es) 2013-04-04
EP2061794B1 (en) 2012-12-05
CA2660957A1 (en) 2008-02-28
TW200825089A (en) 2008-06-16
US8759361B2 (en) 2014-06-24
EP2061794A4 (en) 2010-09-08
US20120208829A1 (en) 2012-08-16
AU2007288203A1 (en) 2008-02-28
WO2008024438A3 (en) 2008-11-27
CO6150167A2 (es) 2010-04-20
NO20091182L (no) 2009-05-14

Similar Documents

Publication Publication Date Title
JP5421108B2 (ja) ２−フェノキシピリミジノン類縁体
JP2010501571A (ja) ハロアルキル−置換ピリミジノン誘導体
US20040156869A1 (en) 2-substituted quinazolin-4-ylamine analogues
JP2007509985A (ja) カプサイシン受容体作動薬
JP2006528640A (ja) 置換ピリジン−２−イルアミン類縁体
JP2007520444A (ja) 置換二環式キナゾリン−４−イルアミン誘導体
JP2010509224A (ja) ｃｉｓ−シクロヘキシル置換ピリミジノン誘導体
JP2008528613A (ja) 置換ピリダジニル−及びピリミジニル−キノリン−４−イルアミン類縁体
JP2008526997A (ja) ヘテロアリール置換キノリン−４−イルアミン類縁体
JP2007532570A (ja) 置換シンノリン−４−イルアミン類
JP2007526339A (ja) アリール置換プリン類縁体
JP2008515988A (ja) 置換ビアリールキノリン−４−イルアミン類縁体
US20070219203A1 (en) Arylalkylamino-substituted quinazoline analogues
JP2007526332A (ja) ヘテロアルキル置換ビフェニル−４−カルボン酸アリールアミド類縁体
JP2008523152A (ja) ピペラジニル−ピリジン類縁体
WO2009121036A2 (en) Substituted aryl pyrimidinone derivatives
CN1953979A (zh) 经取代的5,12－二吖－苯幷葱类似物
WO2009100403A1 (en) Substituted aryl pyrimidinones
JP2007537978A (ja) アリール基で置換されたベンゾ［ｄ」イソチアゾール−３−イルアミン類縁体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131121

R150 Certificate of patent or registration of utility model

Ref document number: 5421108

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees